Merck & Co Inc, Rahway, New Jersey, USA
Merck & Co Inc, Rahway, New Jersey, USA.
BMJ Open. 2023 Feb 2;13(2):e065749. doi: 10.1136/bmjopen-2022-065749.
Human papillomavirus (HPV) infection is the most common sexually transmissible infection worldwide. Although the prevalence of cervical HPV infection has been extensively reported in women worldwide, few epidemiological studies have examined the prevalence of non-cervical HPV infection among both women and men, especially in China.
PROGRESS-Plus is a national, multisite, cross-sectional study that aims to estimate the prevalence of non-cervical HPV infection in women and men aged 18-60 years residing in mainland China. More specifically, PROGRESS-Plus will estimate the prevalence rate of HPV DNA in oral samples from both women and men, and that of anogenital samples from men. The secondary study objectives are to (1) report the aforementioned prevalence rates by HPV genotype, age and geographical region, (2) examine the concordance (ie, prevalence of the same HPV genotype) between the oral and anogenital samples among men, (3) explore risk factors associated with oral (in both women and men) and anogenital (in men only) HPV infection and (4) describe study participants' health-related quality of life, health behaviour, sexual behaviour and health status.
The study protocol and all required documents have been submitted for review and approval to the Independent Ethics Committees of all the participating sites. All participants will provide their written informed consent on study entry, and all the recorded data will be treated as confidential.
人乳头瘤病毒(HPV)感染是全球最常见的性传播感染。尽管全球范围内广泛报道了女性宫颈 HPV 感染的流行情况,但很少有流行病学研究调查过女性和男性中非宫颈 HPV 感染的流行情况,尤其是在中国。
PROGRESS-Plus 是一项全国性、多地点、横断面研究,旨在估计中国 18-60 岁女性和男性中非宫颈 HPV 感染的流行率。更具体地说,PROGRESS-Plus 将估计女性和男性的口腔样本中 HPV DNA 的流行率,以及男性的肛门生殖器样本中 HPV DNA 的流行率。次要研究目标是:(1) 按 HPV 基因型、年龄和地理区域报告上述流行率;(2) 检查男性口腔和肛门生殖器样本之间的一致性(即同一 HPV 基因型的流行率);(3) 探讨与口腔(女性和男性)和肛门生殖器(仅男性)HPV 感染相关的危险因素;(4) 描述研究参与者的健康相关生活质量、健康行为、性行为和健康状况。
该研究方案和所有必要文件已提交给所有参与地点的独立伦理委员会进行审查和批准。所有参与者将在入组时提供书面知情同意书,所有记录的数据将被视为机密。